

VIA EDGAR

September 7, 2023

United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention: Alan Campbell

**Re: Tango Therapeutics, Inc.
Acceleration Request for Registration Statement on Form S-3
File No. 333-274298**

Dear Mr. Campbell,

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “**Act**”), Tango Therapeutics, Inc. (the “**Company**”) hereby requests that the effective date of the above-referenced registration statement (the “**Registration Statement**”) be accelerated to September 11, 2023, at 4:01 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling William Collins at (617) 570-1447.

If you have any questions regarding this request, please contact William Collins of Goodwin Procter LLP at (617) 570-1447.

Sincerely,

TANGO THERAPEUTICS, INC.

/s/ Daniella Beckman

Daniella Beckman

Chief Financial Officer

cc: Barbara Weber, MD, *Tango Therapeutics, Inc.*
Douglas Barry, *Tango Therapeutics, Inc.*
William Collins, Esq., *Goodwin Procter LLP*